胃癌患者外周血CD4+ CD25highCD127low/-调节性T细胞表达临床意义分析

目的:研究CD4+CD25highCD127low/-调节性T细胞(Treg)在胃癌患者外周血中的表达水平,探讨其在肿瘤发病机制及治疗中的作用。方法:采用流式细胞术检测法检测90例胃癌患者(35例为早中期胃癌,55例为晚期胃癌)和30名健康体检者外周血中CD4+CD25highCD127low/-Treg的表达水平。结果:90例胃癌患者外周血CD4+T细胞中CD4+CD25highCD127low/-Treg含量为(11.60±5.99)%,高于健康体检者(5.19±1.72)%,t=5.610,P=0.007;Ⅲ+Ⅳ期患者外周血CD4+T细胞中CD4+CD25high CD127low/-Treg含量为(12.55±6.59)%,明显高于Ⅰ+Ⅱ期患者(10.39±4.68)%(t=4.113,P=0.04)和健康体检者(5.19±1.72)%(t=5.923,P=0.001)。手术后胃癌患者CD4+CD25highCD127low/-Treg水平为(6.12±2.13)%,明显低于手术前(11.25±5.63)%,t=5.237,P=0.04。结论:胃癌患者外周血CD4+CD25highCD127low/-Treg数量增多且与病程分期相关,手术后Treg数量明显减少,Treg可能参与了胃癌的发生发展。     

甲状腺乳头状癌患者外周血CD4+CD25+CD127low/-Treg的检测及其临床意义

目的:检测CD4+ CD25+ CD127low/-调节性T细胞(regulatory T cell,Treg)在甲状腺乳头状癌(papillary thyroid carcinoma,PTC)患者外周血的比例,探讨其临床意义。方法:选择2010年8月至2011年2月在上海交通大学医学院附属仁济医院进行手术治疗的PTC患者40例及甲状腺腺瘤患者30例,以CD4+ CD25+ CD127low/-为标志,采用流式细胞术检测PTC患者及甲状腺腺瘤患者外周血中CD4+ CD25+ CD127low/-Treg的比例,分析其与PTC临床病理特征的关系。结果:与甲状腺腺瘤患者比较,PTC患者外周血中CD4+ CD25+ CD127low/- Treg比例明显升高[(7.836±1.668)% vs(5.365±1.156)%,P<0.05];外周血CD4+ CD25+ CD127low/-Treg比例与PTC临床分期、颈部淋巴结转移相关(均P<0.05),与年龄、性别及肿瘤大小无关(P>0.05)。结论:PTC患者外周血CD4+ CD25+ CD127low/-Treg比例显著增加,且与PTC临床分期、颈部淋巴结转移相关。     

食管癌患者外周血调节性T细胞亚群格局变化及其临床意义

[目的]分析食管癌患者外周血CD4+CD25+CD127-调节性T细胞(Treg)占CD4+T细胞的比例变化.[方法]采用流式细胞仪检测104例食管癌患者和68例健康及良性疾病对照者外周血中CD4+CD25+CD127-Treg占CD4+T细胞的比例,分析其与临床分期、淋巴结转移及外膜受侵的关系.[结果]食管癌患者与对照组的外周血CD4+CD25+CD127-Treg占CD4+T细胞比例分别为(5.19％±1.82％)和(4.56％±1.16％),两组比较差异有统计学意义(t=2.544,P=0.012).Ⅱa期CD4+CD25+CD 127-Treg细胞比例分别与Ⅱb期和Ⅲa期比较,差异均有统计学意义(P＜0.01);不同年龄、淋巴结及外膜受侵状况患者的外周血CD4+CD25+CD127-Treg细胞比例变化比较无统计学差异(P＞0.05).[结论]食管癌患者外周血CD4+CD25+CD127-Treg占CD4+T细胞的比例明显升高,且分期高患者升高更为明显,提示可能与食管癌免疫逃逸和免疫耐受有关.     

调节性T细胞在甲状腺乳头状癌免疫耐受形成中的作用及意义

目的 研究调节性T细胞(Treg)在甲状腺乳头状癌(PTC)患者外周血和肿瘤微环境中的分布及意义.方法 选择确诊并手术的PTC患者80例作为PTC组,PTC合并桥本氏甲状腺炎(HT)患者80例作为PTC合并HT组,同时选择80例结节性甲状腺肿患者作为对照组.术前用流式细胞仪检测外周血中CD4+CD25+CD127low/-Treg,术后用免疫组化方法检测肿瘤和转移性淋巴结中Foxp3的表达情况.比较各组表达差异及与临床病理特征的关系.结果 外周血中CD4+CD25+CD127low/-Treg比例PTC组患者[(9.01±1.82)％]最高,PTC合并HT组患者[(6.94±1.69)％]次之,对照组患者[(6.01±2.33)％]最低,差异有统计学意义(P﹤0.05);有淋巴结转移、有腺外侵犯的PTC患者外周血CD4+CD25+CD127low/-Treg比例和肿瘤组织中Foxp3高表达者比例均高于无淋巴结转移及无腺外侵犯患者(P﹤0.05).结论 PTC患者外周血及组织微环境中Treg均增加,对癌细胞免疫耐受、组织浸润和转移有促进作用.     

B细胞非霍奇金淋巴瘤患者外周血CD4＋CD25high CD127low调节性T细胞水平及其临床意义

目的 探讨外周血CD4＋ CD25high CD127low调节性T细胞（Treg细胞）在B细胞非霍奇金淋巴瘤（B-NHL）患者外周血中表达水平及其临床意义.方法 采用流式细胞术检测100例初诊B-NHL患者及50名健康对照者外周血CD4＋ CD25high CD127low Treg细胞表达水平,进行统计学分析.结果 健康对照者外周血CD4＋ CD25high CD127low Treg细胞中位表达水平为5.00％,初诊B-NHL患者为7.20％,两者之间差异具有统计学意义（P＜ 0.001）.男性患者外周血CD4＋ CD25high CD 127low Treg细胞水平高于女性患者（P＜0.01）,乳酸脱氢酶（LDH）增高患者外周血CD4＋ CD25high CD127low Treg细胞水平高于LDH正常患者（P＜0.01）,Ⅲ～Ⅳ期患者外周血CD4＋C D25high CD 127low Treg细胞水平较Ⅰ～Ⅱ期患者增高（P＜0.01）,有B症状患者外周血CD4＋ CD25high CD127low Treg细胞水平高于无B症状患者（P＜0.01）.而不同年龄、国际预后指数评分、有无大包块患者之间外周血CD4＋ CD25high CD 127low Treg细胞水平差异均无统计学意义（均P＞0.05）.结论 B-NHL患者体内存在免疫抑制,在男性、LDH增高、有B症状及晚期患者中CD4＋ CD25high CD127low Treg细胞水平明显增高.检测其水平对于判断B-NHL的预后有一定价值.     

晚期肺癌患者外周血Treg细胞与NK细胞及其活化受体检测临床意义的探讨

目的:观察CD4+CD25highCD127low调节性T细胞(Treg细胞)、NK细胞及其活化受体(NKG2D)在初诊晚期肺癌患者外周血中的变化,探讨它们在肺癌发病中的作用及临床意义。方法:流式细胞术检测90例初诊晚期肺癌患者及45位健康人外周静脉血CD4+CD25highCD127lowTreg细胞、NK细胞及NKG2D的水平,并就其中27例患者化疗前后数据对比。结果:与对照组比较,肺癌组CD4+CD25highCD127lowTreg细胞比例明显升高,t=3.500,P=0.001;NK细胞比例及NKG2D的表达明显降低,t值分别为-3.534和-5.228,P值均为0.001。Ⅳ期患者CD4+CD25highCD127lowTreg细胞比例较ⅢA期患者明显升高,F=3.657,P=0.030。化疗后患者NK细胞及NKG2D较化疗前明显降低,t值分别为3.176和2.771,P值分别为0.004和0.01。化疗前后患者CD4+CD25highCD127lowTreg细胞水平差异无统计学意义,t=1.419,P=0.168。肺癌患者外周血CD4+CD25highCD127lowTreg细胞比例与NK细胞比...     

贲门癌患者外周血CD4+CD25hiCD127low调节性T细胞水平及其临床意义

目的 探讨贲门癌患者的免疫功能异常及其临床意义.方法 采用流式细胞术(FCM)和酶联免疫吸附(ELISA)方法分别检测56例贲门癌患者、15名健康人外周血中CD4+CD25hiCD127lowc调节性T细胞(Treg细胞)和血清IL-10、TGF-β1水平,结合临床资料进行分析.结果 56例贲门癌患者外周血中CD4+CD25hiCD127lowTreg细胞占CD4+淋巴细胞的比例为(5.73±1.56)%,与健康对照组的(4.45±1.06)%相比,差异有统计学意义(P<0.01);血清中IL-10和TGF-β1含量均明显高于健康对照(P<0.05).贲门癌患者外周血CD4+CD25hiCD127low Treg细胞水平与血清IL-10和TGF-β1含量呈正相关.贲门癌患者外周血CD4+CD25hiCD127low Treg细胞数量与患者临床分期、淋巴结转移有关.结论 贲门癌患者外周血中CD4+CD25hiCD127low Treg细胞表达增高,与临床分期有关,提示Treg水平异常与贲门癌的发生发展密切相关.     

艾迪注射液辅助化疗对中晚期非小细胞肺癌患者CD+4CDhi25CDlow127调节性T细胞表达的影响

目的 探讨艾迪注射液辅助化疗对中晚期非小细胞肺癌(NSCLC)患者外周血CD+4CDhi25CDlow127调节性T(Treg)细胞表达的影响.方法 60例NSCLC患者随机分为化疗加艾迪注射液组(观察组)和单纯化疗组(对照组),采用流式细胞术(FCM)和酶联免疫吸附法(ELISA)分别于化疗前后检测外周血中CD+4CDhi25CDlow127Treg细胞和血清TGF-β 1、IL-10水平,同期选取20名健康体检者为健康对照组.结果 NSCLC患者外周血中CD+4CDhi25CDlow127Treg细胞占CD+4淋巴细胞的比例为(5.77±1.50)%,与健康对照组(3.84±0.96)%相比差异有统计学意义(P=0.000);血清中IL-10和TGF-β 1表达水平[(24.09±6.74)、(197.76±43.76)ng/ml]明显高于健康对照[(19.39±5.73)、(141.13±32.17)ng/ml](P=0.006,P=0.002).对照组化疗后CD+4CDhi25CDlow127Treg细胞水平显著降低(P=0.048),细胞因子IL-10、TGF-β1的表达水平[(22.25±6.79)、(184.85±49.11)ng/ml]与化疗前[(24.37±8.10)、(197.16±44.57)ng/ml]相比差异无统计学意义(P=0.276,P=0.314).观察组化疗后CD+4CDhi25CDlow127Treg细胞和细胞因子IL-10、TGF-β1表达水平[(4.36±1.19)%,(20.16±4.73)、(165.42±39.57)ng/ml]与化疗前[(5.78±1.50)ng/ml,(23.81±5.15)、(198.35±43.68)ng/ml]相比降低,差异有统计学意义(P=0.000,P=0.006,P=0.003).结论 中晚期NSCLC患者外周血中Treg细胞表达水平增高,艾迪注射液配合化疗可以降低NSCLC患者的Treg细胞水平,改善机体免疫状态.     

肺癌患者外周血CD4+CD25+调节性T细胞检测的临床意义

目的:探讨肺癌患者外周血CD4+CD25+调节性T细胞(Treg)的比例变化及其在肿瘤发生发展中的作用.方法:应用流式细胞术检测78例肺癌患者和30例健康者CD4+CD25+Treg比例,分析其与肺癌的临床分期、病理类型、组织学分化程度及手术的关系.结果:肺癌患者外周血CD4+CD25+Treg比例与健康对照组比较,差异有统计学意义,t=2.316,P=0.04.Ⅲ、Ⅳ期肺癌患者Treg比例显著高于Ⅰ+Ⅱ期患者,t值分别为2.205和2.207,P值均为0.04.鳞癌、腺癌、小细胞肺癌高、中和低分化肺癌患者Treg比例显著高于对照组,P<0.05.手术后的肺癌患者Treg比例为(14.38±3.82)%,显著低于手术前的(20.16±5.24)%,t=1.823,P=0.05.结论:肺癌患者外周血CD4+CD25+Treg水平明显升高,且与肺癌的进展密切相关,越晚期水平越高;手朱后肺癌总着外鼠血CD4+CD25+Treg水平明显下调.     

DC-CIK对胃癌合并腹水患者外周血CD4+CD25+调节性T细胞增殖及功能的影响

目的:探讨DC-CIK对胃癌合并腹水患者外周血CD4+CD25+调节性T胞(Treg细胞)比例及功能的影响。方法:60例胃癌合并腹水患者,于输注DC-CIK前1天及DC-CIK治疗结束后1周分别采集外周血。流式细胞术检测外周血Treg细胞的比例,RT-PCR法检测其Foxp3mRNA表达情况;将分选出的Treg细胞和CD4+CD25-T细胞分为单纯Treg细胞组（A组）、1∶1混合培养（B组）、单纯CD4+CD25-细胞组（C组）进行培养,3H-TdR掺入法检测Treg细胞抑制CD4+CD25-细胞增殖的能力。结果:治疗后外周血Treg细胞占CD4+T细胞的比例较疗前显著下降［(6.21±1.37)% vs (9.38±1.06)%,P＜0.05］。治疗后Treg细胞Foxp3mRNA表达水平较治疗前显著下降［(56.18±13.25)% vs (85.26±11.58)%,P＜0.05］。治疗后Treg对CD4+CD25-T细胞抑制增殖能力较治疗前明显下降［(37.31±4.16)% vs (48.92±5.25)%,P＜0.05］。结论:输注DC-CIK免疫治疗,可显著降低胃癌合并腹水患者外周血Treg细胞比例,下调Foxp3mRNA表达水平,降低Treg细胞免疫抑制功能,有利于诱导抗肿瘤免疫效应。     

Enhanced myeloid specificity of CD117 compared with CD13 and CD33

The c-kit proto-oncogene encodes a 145 kd tyrosine kinase transmembrane receptor, which plays a key role in haemopoiesis. The c-kit has been classified as CD117 and is especially useful in the differential diagnosis of acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). We analysed 104 consecutive cases (55 AML, 23 B-cell lineage ALL, three T-cell ALL, 11 blast crisis of chronic myeloproliferative disorders and 12 cases of myelodysplastic syndromes with more than 10% of blasts) referred to our Hospital for immunophenotypic diagnosis and compared the expression pattern of CD13, CD33 and CD117 using the same fluorochrome (phycoerythrin-PE). The recommendations of the EGIL group were followed in order to establish lineage involvement of the blastic population. The threshold used to assign positivity for CD117 was 10%. Bcr/abl, TEL/AML-1 and MLL rearrangements were assessed by molecular methods. CD117 expression was detected in 91% of AML and MDS. All the negative cases corresponded to acute monocytic leukemias. The calculated specificity for myeloid involvement was 0.86 for CD117, 0.36 for CD13 and 0.44 for CD33 (P < 0.005). CD117 was also positive in four cases of ALL. None of these cases showed bcr/abl or MLL rearrangements. In the light of these findings, CD117 expression should yield a higher score, at least one point, in the system currently applied for the diagnosis of biphenotypic acute leukemias (BAL) as its myeloid specificity is greater than that of CD13 and CD33. Moreover, its absence in AML could identify two subgroups of M5b cases. The coexpression of CD117 with cytoplasmic CD79a is often associated with CD7 reactivity, suggesting a stem cell disorder. CD117 should be included on a routine basis for the immunophenotypic diagnosis of acute leukemias.     

CD46 CD55 CD59在结肠癌组织中的表达及意义

目的:检测CD46、CD55、CD59在结肠癌组织中的表达情况,分析其与结肠癌临床病理参数间的相关性及意义。方法:选取有详细性别、年龄、组织分化、病理分期、肿瘤部位、组织类型资料的组织芯片标本,包括121 例结肠癌和121 例癌旁结肠组织,均为2004年10月至2006年6 月第四军医大学西京消化病医院胃肠外科手术切除标本。应用免疫组织化学改良二步法分别检测CD46、CD55、CD59的表达情况。结果:CD46、CD55及CD59在结肠癌组织中的阳性表达率均显著高于对应的癌旁组织（P < 0.001）。 CD46表达水平与性别、年龄、组织分化、TNM 病理分期、肿瘤位置、病理组织类型均无关（P > 0.05）。 CD55、CD59的表达水平与性别、年龄、肿瘤位置、病理类型无关（P > 0.05）,而与组织分化、TNM 病理分期有关（P < 0.05）。 其表达强度阳性率中低分化组明显高于高分化组（P < 0.05）。 TNM 分期中Ⅲ、Ⅳ期患者肿瘤病理组织强阳性表达率高于Ⅰ、Ⅱ期阳性表达率,两者比较有统计学意义（P < 0.05）。 结论:CD46、CD55及CD59在结肠癌组织中高表达,特别是CD55、CD59的表达与肿瘤分化、病理分期相关,提示三者表达水平与结肠癌生物学行为密切相关。      

Poor prognosis of mediastinal non-Hodgkin's lymphoma with an immature phenotype of CD2+, CD7 (or CD5)+, CD3-, CD4-, and CD8-

Nine children with mediastinal non-Hodgkin's lymphoma (NHL) were treated according to our new regimen which is characterized by intensified therapy with high-dose cytosine arabinoside (HDCA). After induction therapy with a combination of five drugs, such as vincristine, doxorubicin, cyclophosphamide, 1-asparaginase, and prednisolone, intermediate dosages of methotrexate (MTX) (1 g/m2) and HDCA (1.5 g/m2 x 12 doses) were administered. All but one patient (88.9%) achieved complete remission and then received this intensified therapy. With a median follow-up period of 25.5 months, five patients are still in complete remission, but three patients have relapsed. From the phenotypic point of view, these relapsed patients showed only very immature T-cell differentiation antigens such as CD2 and CD7 (or CD5). These results suggest that HDCA as intensified therapy for children with mediastinal NHL seems to be effective. However, for patients with an immature phenotype of T-lineage cells, more sophisticated regimens should be prepared.     

CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia

CD5, CD10, and CD23 are cell surface antigens used to distinguish B-cell disorders. The expression of these antigens and their clinical significance in Waldenstrom's macroglobulinemia (WM), an uncommon B-cell disorder, remains to be clarified. We therefore determined expression of CD5, CD10, and CD23 by flow cytometric analysis on bone marrow lymphoplasmacytic cells (CD19+ k/l light chain restricted) for 171 serially biopsied patients with findings of the consensus panel definition of WM. Importantly, we also correlated laboratory and clinical data, as well as existence of a familial history of a B-cell disorder in view of reports suggesting familial predisposition in WM. These studies demonstrated tumor cell expression of CD5, CD10, and CD23 in 15 of 171 patients (9%), 11 of 161 patients (7%), and 37 of 105 patients (35%), respectively. Coexpression of CD23 with CD5 or CD10 was common. Tumor Lymphoplasmacytic from 10 of 15 (66%) and 3 of 11 (27%) patients with WM that expressed CD5 and CD10, respectively, also showed expression of CD23 (P = 0.01 and P = 0.08, respectively). Among patients with CD23 expression, increased serum immunoglobulin (Ig) M levels were observed compared with patients without CD23 expression (P = 0.05). No differences in age at diagnosis; presence of adenopathy and/or splenomegaly; bone marrow involvement; serum IgA, IgB, and b2 macroglobulin levels; hematocrit; platelet count; or familial history of WM or a related B-cell disorder were observed among patients with and without CD5, CD10, and CD23 expression. These studies demonstrate that CD5, CD10, and CD23 are commonly found in WM and that their expression should not exclude the diagnosis of WM. Moreover, expression of CD23 may define a clinically distinct subset of patients with WM.     

经典型霍奇金淋巴瘤CD15及CD30蛋白表达的研究

目的：探讨CD15和CD30在经典型霍奇金淋巴瘤（cHL)H/RS细胞的表达及区别。方法：采用SABC法对32例cHL中CD15和CD30蛋白的表达进行检测。结果：CD15阳性25例,阳性率为78．1％,CD30阳性30例,阳性率为93．8％,各型之间阳性表达没有显著性差异,2例蛋白表达之间也无显著性差异。结论：CD15和CD30均可作为cHL的诊断免疫标记。     

人CD46、CD55和CD59与肿瘤免疫逃逸及免疫治疗

膜结合补体调节蛋白CD46、CD55和CD59在肿瘤细胞膜上表达或过表达,保护肿瘤细胞免受免疫系统的攻击,成为肿瘤细胞免疫逃逸的途径之一.如何下调肿瘤细胞表面三者表达或抑制其功能以增强其对补体依赖的细胞毒作用的敏感性备受关注.     

A child case of CD34, CD33, HLA-DR, CD7, CD56 stem cell leukemia with thymic involvement

It has been reported that the CD56⁺/CD7⁺/CD3⁻ phenotype of natural killer (NK) cells develop from the CD34⁺/HLA-DR⁻ bone marrow (BM) mononuclear cell population in long-term BM culture (LTBMC). An HLA-DR⁻/CD33⁺/CD56⁺/CD16⁻ myeloid/natural killer cell acute leukemia has been described. We report here a 7-year-old boy who developed stem cell acute leukemia with superior vena cava syndrome secondary to thymic involvement. Surface marker analyses revealed that the leukemia cells showed CD34⁺/HLA-DR⁻/CD33⁻/CD7⁺/CD56⁺ phenotype. When stimulated with phorbol ester in vitro the leukemic cells morphologically differentiated to myeloid cells developing CD13, CD15 and CD56 antigens. Our results suggest that CD34⁺/HLA-DR⁻/CD7⁺/CD56⁺ stem cell leukemia may arise from transformation of a pluripotent precursor cell, which could differentiate to both myeloid and NK cell lineages.